SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
SulAmérica is one of the largest insurance companies in Brazil and operates in the health and dental insurance, life and pension plans, and asset management sectors. The company was founded in 1895 and is headquartered in Rio de Janeiro, Brazil.
Rede D’Or is the largest integrated healthcare network in Brazil, operating in the health sector, with an extensive network of private hospitals.
One of Oaklins’ teams in Brazil acted as the sole financial advisor to SulAmérica on its combination with Rede D’Or São Luiz S.A. The transaction will be submitted for approvals at shareholders’ meetings of both companies and to relevant regulatory agencies. Once the closing date is defined the companies will inform the market.
Contacter l'équipe de la transaction
Richard Rainer
Oaklins Olimpia Partners
Transactions connexes
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
En apprendre plusRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
En apprendre plusCenterbridge Partners has announced a minority interest investment in Pure Cremation
Centerbridge Partners, L.P. has announced a structured minority interest investment in Pure Cremation. The investment includes both loan and equity instruments and is subject to regulatory approval, with completion expected in the first half of 2026.
En apprendre plus